ST6GAL1

Beta-galactoside alpha-2,6-sialyltransferase 1 · P15907 · ST6GAL1 on Sugi Atlas →

12,921 patent compounds predicted against ST6GAL1, 8,822 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL584780	0.56	15/20
SCHEMBL607765	0.56	15/20
SCHEMBL600526	0.44	15/20
Aceneuramic Acid (SCHEMBL237563)	0.49	14/20
SCHEMBL801929	0.79	13/20
SCHEMBL588782	0.51	13/20
SCHEMBL1794713	0.65	12/20
Sialic Acid (SCHEMBL2296552)	0.50	11/20
SCHEMBL800664	0.38	11/20
SCHEMBL800827	0.38	11/20
SCHEMBL881938	0.38	11/20
SCHEMBL881973	0.38	11/20
Cytarabine 5'-Phosphate (SCHEMBL859798)	0.70	10/20
Cytarabine 5'-Phosphate (SCHEMBL2370501)	0.70	10/20
Cystetine Triphosphate (SCHEMBL2194120)	0.67	10/20
Cystetine Triphosphate (SCHEMBL2194115)	0.66	10/20
Citicoline (SCHEMBL667104)	0.65	10/20
Choline (SCHEMBL503814)	0.62	10/20
Pyrophosphoric Acid (SCHEMBL760216)	0.61	10/20
Choline (SCHEMBL2446082)	0.61	10/20

Clinical trials — most relevant to ST6GAL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis	PHASE2	RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
The Natural History of Sialidosis Type I	nan	RECRUITING
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
GALNT4 in Patients With Acute Coronary Syndrome	nan	COMPLETED
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy	nan	UNKNOWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ST6GAL1 binder may also engage these)

Protein	Name	Similarity
Q64685	—	1.000	Q64685 →
P13721	—	0.999	P13721 →
Q11206	—	0.996	Q11206 →
Q92182	—	0.994	Q92182 →
P61130	—	0.994	P61130 →
Q70D51	—	0.994	Q70D51 →
Q701R0	—	0.993	Q701R0 →
Q02734	—	0.993	Q02734 →
Q9QZ39	—	0.993	Q9QZ39 →
Q92183	—	0.993	Q92183 →
Q91Y74	—	0.993	Q91Y74 →
P61131	—	0.992	P61131 →
Q9UNP4	—	0.992	Q9UNP4 →
Q6KB55	—	0.991	Q6KB55 →
Q68G12	—	0.991	Q68G12 →
P70277	—	0.991	P70277 →
Q701R2	—	0.991	Q701R2 →
Q02745	—	0.991	Q02745 →
P61132	—	0.991	P61132 →
ST3GAL3	CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase	0.991	landscape →
Q08E15	—	0.991	Q08E15 →
ST3GAL1	CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1	0.989	landscape →
Q6KB54	—	0.989	Q6KB54 →
O88829	—	0.989	O88829 →
Q76K27	—	0.988	Q76K27 →
Q6KB59	—	0.988	Q6KB59 →
Q8K4T1	—	0.988	Q8K4T1 →
Q92184	—	0.988	Q92184 →
P97325	—	0.988	P97325 →
Q701R3	—	0.988	Q701R3 →